Skip to main content
OpenTrials
Completed

NCT Number: NCT04500860

Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.

Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Samer Morsy

Cairo, 12334, Egypt

About this study

90 female patients with overactive bladder syndrome divided into 3 groups group A subjected to daily low dose tadalafil 5 mg ,group B subjected to tolterodine and group C to placebo. They are evaluated as using OAB symptoms score for 6 months follow up

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • any female with overactive bladder syndrome, urgency with or without urgency urinary incontinence

Exclusion criteria

  • Active Urinary tract infection
  • neurologic abnormality
  • Pure Stress urinary incontinence

Treatment and study plan

Low dose tadalafil 5 mg

Drug

Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence

Tolterodine 4 Mg Oral Capsule, Extended Release

Drug

To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder

Placebo

Drug

Placebo drugs

Primary outcomes

  1. Efficacy of daily low dose tadalafil 5mg in treatment of female overactive bladder syndrome: 6 months follow up

    Time frame: 6 months

    Evaluation of efficacy of tadalafil 5 mg

Sponsors and collaborators

Lead sponsor

Kasr El Aini Hospital

Other

Registry information

Official study title

Low Dose Tadalafil 5mg for Treatment of Female Overactive Bladder Syndrome :6 Months Follow up

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Aug 5, 2020
Registry last updated
Aug 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.